JP4318398B2 - クロストリジウム・ディフィシレ・トキシンａ - Google Patents

クロストリジウム・ディフィシレ・トキシンａ Download PDF

Info

Publication number
JP4318398B2
JP4318398B2 JP2000510776A JP2000510776A JP4318398B2 JP 4318398 B2 JP4318398 B2 JP 4318398B2 JP 2000510776 A JP2000510776 A JP 2000510776A JP 2000510776 A JP2000510776 A JP 2000510776A JP 4318398 B2 JP4318398 B2 JP 4318398B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
clostridium difficile
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000510776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515920A (ja
JP2001515920A5 (https=
Inventor
フォン アイヒェル−シュトライバー クリストフ
モース ミヒャエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2001515920A publication Critical patent/JP2001515920A/ja
Publication of JP2001515920A5 publication Critical patent/JP2001515920A5/ja
Application granted granted Critical
Publication of JP4318398B2 publication Critical patent/JP4318398B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000510776A 1997-09-10 1998-09-10 クロストリジウム・ディフィシレ・トキシンａ Expired - Fee Related JP4318398B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19739685.2 1997-09-10
DE19739685A DE19739685A1 (de) 1997-09-10 1997-09-10 Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
PCT/EP1998/005759 WO1999012971A2 (de) 1997-09-10 1998-09-10 Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine

Publications (3)

Publication Number Publication Date
JP2001515920A JP2001515920A (ja) 2001-09-25
JP2001515920A5 JP2001515920A5 (https=) 2006-01-05
JP4318398B2 true JP4318398B2 (ja) 2009-08-19

Family

ID=7841840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510776A Expired - Fee Related JP4318398B2 (ja) 1997-09-10 1998-09-10 クロストリジウム・ディフィシレ・トキシンａ

Country Status (11)

Country Link
US (2) US6667035B1 (https=)
EP (1) EP0994904B1 (https=)
JP (1) JP4318398B2 (https=)
CN (1) CN1273588A (https=)
AT (1) ATE254139T1 (https=)
AU (1) AU9742698A (https=)
BR (1) BR9815367A (https=)
CA (1) CA2303202C (https=)
DE (2) DE19739685A1 (https=)
ES (1) ES2210832T3 (https=)
WO (1) WO1999012971A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
WO2002062379A2 (en) * 2001-02-09 2002-08-15 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0205206D0 (en) * 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
ATE385423T1 (de) * 2004-06-16 2008-02-15 Straumann Holding Ag Abdeckmembran
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
CA2618796C (en) 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20090280134A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
CA2768528C (en) * 2009-07-27 2017-05-23 Christoph Von Eichel-Streiber Method for detecting and identifying a variant c. difficile strain in a sample
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012118693A1 (en) * 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9505847B2 (en) * 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
HK1200463A1 (en) * 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
DE3471661D1 (en) 1984-03-02 1988-07-07 Tracy Dale Wilkins Toxins and antibodies of c. difficile
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4863852A (en) 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5098826A (en) 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Also Published As

Publication number Publication date
DE19739685A1 (de) 1999-03-11
ES2210832T3 (es) 2004-07-01
AU9742698A (en) 1999-03-29
JP2001515920A (ja) 2001-09-25
BR9815367A (pt) 2001-11-06
EP0994904B1 (de) 2003-11-12
CA2303202A1 (en) 1999-03-18
EP0994904A2 (de) 2000-04-26
ATE254139T1 (de) 2003-11-15
WO1999012971A3 (de) 1999-07-22
US7151159B2 (en) 2006-12-19
CA2303202C (en) 2010-04-27
US6667035B1 (en) 2003-12-23
DE59810172D1 (de) 2003-12-18
CN1273588A (zh) 2000-11-15
WO1999012971A2 (de) 1999-03-18
US20040137601A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
JP4318398B2 (ja) クロストリジウム・ディフィシレ・トキシンａ
JP5744872B2 (ja) 親和性成熟ヒト化抗ｃｅａモノクローナル抗体
JP3786695B2 (ja) 修飾した抗原性免疾グロブリンによるｔ細胞の活性化
EP1383785B1 (en) Recombinant tumor specific antibody and use thereof
AU2012298877B2 (en) Clostridium difficile antibodies
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
RU2687588C2 (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
EP2968508B1 (en) Antibodies against clostridium difficile toxins and methods of using the same
AU2004245038A1 (en) De-immunized anti-CD3 antibody
AU2013352034B2 (en) Antibodies against Clostridium difficile
MX2013014388A (es) Exotoxina a de pseudomonas con epitopos de linfocitos t y/o linfocitos b menos inmunogenicos.
CN115087673A (zh) 结合il4r的抗体及其用途
KR20150073211A (ko) 항―캄필로박터 제주니 항체 및 그의 용도
KR20210069058A (ko) 항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
WO2007071061A1 (en) Methods for generating and screening fusion protein libraries and uses thereof
EP1079856B1 (en) Humanized antibodies that recognize verotoxin ii and cell line producing same
JP2004506695A (ja) う蝕の予防の免疫学的方法
MXPA00002491A (en) Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile
Tout et al. Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide
HK40079597A (en) Antibodies binding il4r and uses thereof
KR100506118B1 (ko) 수막염균증 백신 조성물
HK40076787B (zh) 抗angptl3抗体及其应用
Boese Copyright© 2008 by Darren Jacob Boese
HK1036215B (en) Humanized antibodies that recognize verotoxin ii and cell line producing same
Williamson Characterisation of Bordetella pertussis Antigens and Production of Human Recombinant Antibodies to These Antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090305

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090513

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090526

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120605

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees